4.7 Review

Immunotherapy for Brain Tumors

期刊

JOURNAL OF CLINICAL ONCOLOGY
卷 35, 期 21, 页码 2450-+

出版社

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2017.72.8089

关键词

-

类别

资金

  1. Agenus
  2. TCR2 Therapeutics
  3. Kyn
  4. Unum Therapeutics
  5. Novartis
  6. Tmunity Therapeutics

向作者/读者索取更多资源

Glioblastoma (GBM) is the most lethal form of brain tumor and remains a large, unmet medical need. This review focuses on recent advances in the neurosciences that converge with the broader field of immuno-oncology. Recent findings in neuroanatomy provide a basis for new approaches of cellular therapies for tumors that involve the CNS. The ultimate success of immunotherapy in the CNS will require improved imaging technologies and methods for analysis of the tumor microenvironment in patients with GBM. It is likely that combinatorial approaches with targeted immunotherapies will be required to exploit the vulnerabilities of GBM and other brain tumors. (C) 2017 by American Society of Clinical Oncology

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据